Yasutomi, E.; Hiraoka, S.; Yamamoto, S.; Oka, S.; Hirai, M.; Yamasaki, Y.; Inokuchi, T.; Kinugasa, H.; Takahara, M.; Harada, K.;
et al. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. J. Clin. Med. 2019, 8, 2109.
https://doi.org/10.3390/jcm8122109
AMA Style
Yasutomi E, Hiraoka S, Yamamoto S, Oka S, Hirai M, Yamasaki Y, Inokuchi T, Kinugasa H, Takahara M, Harada K,
et al. Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. Journal of Clinical Medicine. 2019; 8(12):2109.
https://doi.org/10.3390/jcm8122109
Chicago/Turabian Style
Yasutomi, Eriko, Sakiko Hiraoka, Shumpei Yamamoto, Shohei Oka, Mami Hirai, Yasushi Yamasaki, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, Keita Harada,
and et al. 2019. "Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents" Journal of Clinical Medicine 8, no. 12: 2109.
https://doi.org/10.3390/jcm8122109
APA Style
Yasutomi, E., Hiraoka, S., Yamamoto, S., Oka, S., Hirai, M., Yamasaki, Y., Inokuchi, T., Kinugasa, H., Takahara, M., Harada, K., Kato, J., & Okada, H.
(2019). Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. Journal of Clinical Medicine, 8(12), 2109.
https://doi.org/10.3390/jcm8122109